Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Morgan Stanley

Equities researchers at Morgan Stanley started coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a report issued on Tuesday, MarketBeat.com reports. The firm set an “overweight” rating and a $40.00 price target on the stock. Morgan Stanley’s price target would indicate a potential upside of 54.86% from the company’s previous close.

Several other equities analysts have also issued reports on DYN. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Raymond James boosted their target price on Dyne Therapeutics from $27.00 to $56.00 and gave the stock a “strong-buy” rating in a research report on Thursday, January 4th. Piper Sandler boosted their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, March 6th. Finally, Chardan Capital boosted their price objective on Dyne Therapeutics from $20.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.75.

Dyne Therapeutics Stock Up 2.1 %

Shares of DYN stock opened at $25.83 on Tuesday. The stock has a 50-day moving average price of $26.21 and a 200 day moving average price of $18.18. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -6.56 and a beta of 0.95. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). Sell-side analysts predict that Dyne Therapeutics will post -3.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 2,292 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.70, for a total value of $58,904.40. Following the sale, the chief operating officer now owns 156,800 shares in the company, valued at approximately $4,029,760. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Dyne Therapeutics news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total value of $4,164,187.57. Following the sale, the insider now owns 6,631,464 shares in the company, valued at approximately $149,672,142.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Susanna Gatti High sold 2,292 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.70, for a total value of $58,904.40. Following the sale, the chief operating officer now owns 156,800 shares in the company, valued at approximately $4,029,760. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,875,432 shares of company stock worth $44,368,530. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. Fcpm Iii Services B.V. bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth approximately $81,543,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $15,758,000. Commodore Capital LP acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $11,970,000. Vivo Capital LLC increased its holdings in shares of Dyne Therapeutics by 58.0% during the 1st quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock worth $46,422,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Braidwell LP increased its holdings in shares of Dyne Therapeutics by 32.2% during the 3rd quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock worth $16,325,000 after acquiring an additional 444,100 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.